UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis

Cell cycle (Georgetown, Tex.), 2016-12, Vol.15 (23), p.3210-3219

2016

Volltextzugriff (PDF)

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

Molecular therapy. Nucleic acids, 2015-04, Vol.4 (4), p.e237-e237, Article e237

2015

Volltextzugriff (PDF)

CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1

Cancer Immunology, Immunotherapy, 2020-01, Vol.69 (1), p.103-114

2020

Volltextzugriff (PDF)

Induction of antigen‐specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment

International journal of cancer, 2016-08, Vol.139 (4), p.841-853

2016

Volltextzugriff (PDF)

Expression, Purification, and Properties of a Human Arachidonoyl-Specific Isoform of Diacylglycerol Kinase

Biochemistry (Easton), 2017-03, Vol.56 (9), p.1337-1347

2017

Volltextzugriff (PDF)

Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury?

Frontiers in immunology, 2022-03, Vol.13, p.836837-836837

2022

Volltextzugriff (PDF)

Slow binding kinetics of secreted protein, acidic, rich in cysteine‐VEGF interaction limit VEGF activation of VEGF receptor 2 and attenuate angiogenesis

The FASEB journal, 2015-08, Vol.29 (8), p.3493-3505

2015

Volltextzugriff (PDF)

342 Improving TCR-T cell function against solid tumors with immune enhancing edits

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A391-A391

2023

Volltextzugriff (PDF)

A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo

Molecular therapy. Nucleic acids, 2018-09, Vol.12, p.350-358

2018

Volltextzugriff (PDF)

Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival

Molecular therapy. Nucleic acids, 2014-08, Vol.3 (8), p.e190-e190, Article e190

2014

Volltextzugriff (PDF)

Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles

Ultrasound in medicine & biology, 2019-02, Vol.45 (2), p.500-512

2019

Volltextzugriff (PDF)

A powerful ICOS agonist that enhances anti-tumor immune responses restored by immune checkpoint inhibitors

The Journal of immunology (1950), 2019-05, Vol.202 (1_Supplement), p.71-71.5

2019

Volltextzugriff (PDF)

Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome

JNCI : Journal of the National Cancer Institute, 2018-12, Vol.110 (12), p.1418-1421

2018

Volltextzugriff (PDF)

Abstract B032: Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.B032-B032

2016

Volltextzugriff (PDF)

Serum‐derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA‐expressing tumor cells

International journal of cancer, 2018-10, Vol.143 (8), p.1963-1977

2018

Volltextzugriff (PDF)

1037 Adoptive cell therapy with genetically engineered t-cells for epithelial ovarian cancer

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A511-A511

2024

Volltextzugriff (PDF)

A Novel Strategy for Off-the-Shelf T Cell Therapy Which Evades Allogeneic T Cell and NK Cell Rejection

Blood, 2021-11, Vol.138 (Supplement 1), p.1711-1711

2021

Volltextzugriff (PDF)

NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Blood, 2020-11, Vol.136 (Supplement 1), p.32-33

2020

Volltextzugriff (PDF)

Abstract A20: Enhancing checkpoint inhibitor therapy with ultrasound stimulated microbubbles

Cancer immunology research, 2020-04, Vol.8 (4_Supplement), p.A20-A20

2020

Volltextzugriff (PDF)

S erum‐derived carcinoembryonic antigen ( CEA ) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA ‐expressing tumor cells

International journal of cancer, 2018-10, Vol.143 (8), p.1963-1977

2018

Volltextzugriff (PDF)

A cross species CD200R1 immune checkpoint agonist with potent anti-inflammatory properties

The Journal of immunology (1950), 2017-05, Vol.198 (1_Supplement), p.194-194.24

2017

Volltextzugriff (PDF)

Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-based Therapeutics

Prodeus, Aaron

2018

Volltextzugriff (PDF)

The Basis of the Substrate Specificity of the Epsilon Isoform of Human Diacylglycerol Kinase is not a Consequence of Competing Hydrolysis of ATP

The FASEB journal, 2013-04, Vol.27 (S1)

2013

Volltextzugriff (PDF)

Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity

JCI insight, 2018-08, Vol.3 (15)

2018

Volltextzugriff (PDF)

Induction of antigen‐specific T H 9 immunity accompanied by mast cell activation blocks tumor cell engraftment

International journal of cancer, 2016-08, Vol.139 (4), p.841-853

2016

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(33)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1

Induction of antigen‐specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment

Expression, Purification, and Properties of a Human Arachidonoyl-Specific Isoform of Diacylglycerol Kinase

Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury?

Slow binding kinetics of secreted protein, acidic, rich in cysteine‐VEGF interaction limit VEGF activation of VEGF receptor 2 and attenuate angiogenesis

342 Improving TCR-T cell function against solid tumors with immune enhancing edits

A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo

Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival

Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles

A powerful ICOS agonist that enhances anti-tumor immune responses restored by immune checkpoint inhibitors

Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome

Abstract B032: Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers

Serum‐derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA‐expressing tumor cells

1037 Adoptive cell therapy with genetically engineered t-cells for epithelial ovarian cancer

A Novel Strategy for Off-the-Shelf T Cell Therapy Which Evades Allogeneic T Cell and NK Cell Rejection

NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Abstract A20: Enhancing checkpoint inhibitor therapy with ultrasound stimulated microbubbles

S erum‐derived carcinoembryonic antigen ( CEA ) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA ‐expressing tumor cells

A cross species CD200R1 immune checkpoint agonist with potent anti-inflammatory properties

Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-based Therapeutics

The Basis of the Substrate Specificity of the Epsilon Isoform of Human Diacylglycerol Kinase is not a Consequence of Competing Hydrolysis of ATP

Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity

Induction of antigen‐specific T H 9 immunity accompanied by mast cell activation blocks tumor cell engraftment

Suchergebnisse filtern